dronedarone hydrochloride - Profile

What are the generic drug sources for dronedarone hydrochloride and what is the scope of freedom to operate?

Dronedarone hydrochloride is the generic ingredient in two branded drugs marketed by Lupin and Sanofi Aventis Us, and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Dronedarone hydrochloride has fifty-eight patent family members in twenty-nine countries.

There are four tentative approvals for this compound.

Summary for dronedarone hydrochloride

International Patents:	58
US Patents:	3
Tradenames:	2
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dronedarone hydrochloride

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dronedarone hydrochloride

Constraining patent/regulatory exclusivity:

8,410,167

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for DRONEDARONE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		400MG	TABLET;ORAL
		400MG	TABLET;ORAL
		400MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DRONEDARONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MULTAQ	Tablets	dronedarone hydrochloride	400 mg	022425	7	2013-07-01

US Patents and Regulatory Information for dronedarone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	DRONEDARONE HYDROCHLORIDE	dronedarone hydrochloride	TABLET;ORAL	205904-001	Jan 31, 2024		DISCN	No	No
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes	8,410,167
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes	9,107,900
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes	8,602,215

Expired US Patents for dronedarone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009	5,223,510
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009	8,318,800
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009	7,323,493

International Patents for dronedarone hydrochloride

Country	Patent Number	Title	Estimated Expiration
South Africa	201007391	USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM IN THE BLOOD
Japan	2011518785
World Intellectual Property Organization (WIPO)	2009144550
Mexico	2010011400	USO DE DRONEDARONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LO MISMO, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE. (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD.)

Supplementary Protection Certificates for dronedarone hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1007030	SPC/GB10/029	United Kingdom		PRODUCT NAME: DRONEDARONE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/09/591/001 20091126; UK EU/1/09/591/002 20091126; UK EU/1/09/591/003 20091126; UK EU/1/09/591/004 20091126
1007030	2010008	Ireland		THE CORRECT SPC EXTENSION DATE IS 20230618 (NOT 20230616); PRODUCT NAME: DRONEDARONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/09/591/001-004 20091126
1007030	10C0031	France		PRODUCT NAME: DRONEDARONE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/591/001 DU 20091126; REGISTRATION NO/DATE AT EEC: EU/1/09/591/001-004 DU 20091126

Investment Scenario, Market Dynamics, and Financial Trajectory of Dronedarone Hydrochloride

Last updated: February 3, 2026

Summary

Dronedarone hydrochloride, marketed as Multaq, is an antiarrhythmic drug developed by Sanofi for managing atrial fibrillation (AF) and atrial flutter. Approved by the U.S. Food and Drug Administration (FDA) in 2009, it is positioned as an alternative to amiodarone with a reportedly reduced risk of thyroid and pulmonary toxicity. Despite its moderate market adoption, its potential remains significant due to the increasing prevalence of atrial fibrillation globally. This report evaluates the investment scenario, market dynamics, and financial trajectory of dronedarone hydrochloride, considering current patent status, competitive landscape, regulatory patterns, and potential growth drivers.

---

1. Investment Landscape for Dronedarone Hydrochloride

Aspect	Details	Implications
Market Capitalization of Sanofi’s Cardiovascular Portfolio	Estimated at USD 35–45 billion (2023)	Indicates robust R&D and market interest; potential for further revenue streams
Patent Status	Original composition patent expired in 2016; exclusivity relies on secondary patents, formulations, or regulatory exclusivities	Patent expiry opens the market for generics, impacting revenues
Generic Entry Threat	Possible post-patent expiration (2024 onward)	Likely significant price erosion, diminishing profit margins
Regulatory Data Exclusivities	Data exclusivity up to 12 years in some jurisdictions (e.g., Europe)	May delay generic competition in specific regions

---

2. Market Dynamics

2.1. Prevalence and Demographics of Atrial Fibrillation

Metric	Value	Source
Global AF Prevalence (2020)	~37 million	[1]
Projected AF Population (2030)	~52 million	[2]
Key Drivers	Aging populations, increasing cardiovascular comorbidities	Growing patient pool for dronedarone

2.2. Competitive Landscape

Key Drugs	Class	Market Share (2023)	Notes
Amiodarone	Class III antiarrhythmic	~65%	First-line agent, but with toxicity concerns
Dronedarone	Class III antiarrhythmic	~15–20%	Niche, particularly for patients intolerant to amiodarone
Other Alternatives	Beta-blockers, calcium channel blockers	Remaining	Used adjunctively or for rate control

Table 1: Key Competitors in Antiarrhythmic Market

2.3. Regulatory and Reimbursement Trends

Region	Policy	Impact on Market
US	Medicare & private insurers known to favor cost-effective generic options	Pressures for price reductions post-patent expiry
EU	Similar policies, with grants for generic and biosimilar entry	Accelerates market entry of generics, decreases revenues for branded drugs

2.4. Clinical Positioning and Safety Profile

Advantage	Disadvantage	Market Influence
Reduced toxicity compared to amiodarone	Less evidence on long-term efficacy	Limits use to specific patient populations

---

3. Financial Trajectory Projections

3.1. Revenue Forecasts

Period	Revenue Estimates (USD Millions)	Assumptions
2023	150–200	Peak post-approval, limited by market share
2024	100–150	Decline due to patent expiry and patent cliff
2025+	< USD 50	Dominance of generics, price erosion

Note: Assumes no new formulations or expanded indications.

3.2. Impact of Patent Expiry

Factor	Potential Effect
Generic Competition	Sharp decline in unit price, volume increase
Market Share	Likely to drop from ~20% to under 5% within 2 years of patent expiry
Pricing Strategies	Premium unmet due to competition; possible market share loss

3.3. R&D and Lifecycle Strategies

Strategy	Expected Outcome
New Formulations/Delivery Systems	Extended patent life, niche market capture
New Indications	Increased revenue streams
Combination Therapies	Higher market penetration

---

4. Comparative Analysis with Similar Drugs

Drug	Year of Patent Expiry	Peak Revenue (USD Millions)	Current Status
Amiodarone	1986, with multiple patents extended until 2028	USD 400+	Dominant, but toxicity limits use
Dronedarone	2016 (patent expiry in 2024)	USD 150–200	Niche, underpricing due to competition

Note: Dronedarone's growth potential depends on its ability to carve niche markets and achieve regulatory exclusivities or new indications.

---

5. Market Entry and Expansion Opportunities

• Biomarker-Driven Patient Stratification: Developing diagnostics for identifying ideal candidates could improve efficacy and adoption.
• Novel Delivery Systems: Formulations such as sustained-release or inhalable options could extend patent protections.
• Combination Therapies: Co-formulation with complementary drugs might demonstrate superior efficacy and safety.

---

6. Comparison and Key Market Challenges

Challenge	Impact	Strategy
Patent Cliff	Revenue decline post-2024	R&D in new formulations, indications
Competition from Generics	Pricing pressure	Early lifecycle management
Clinical Efficacy & Safety Data	Market skepticism	Post-market surveillance, studies
Off-Label Uses	Regulatory risk	Focus on approved indications

---

7. Regulatory and Patent Policy Impact

Policy Area	Effect on Dronedarone
Patent Laws	Patent expiration may erode exclusivity
Data Exclusivity	Can temporarily delay generics
Pricing Regulations	Potentially limit revenue growth
International Regulations	Varying approval timelines

---

8. Key Drivers and Risks

Drivers	Risks
Rising AF prevalence	Patent expiry, market saturation
Growing geriatric population	Competitive pressures
Safety advantages over treatments	Regulatory changes
New indications / formulations	R&D uncertainties

---

9. Conclusions and Strategic Recommendations

Conclusion	Recommendations
Dronedarone has steady yet limited long-term revenue potential due to patent expiry and market competition.	- Invest in lifecycle management through new formulations or indications. - Monitor generic market entry closely. - Focus on niche markets with specific patient populations.
Innovative delivery systems could extend exclusivity and market share.	- Collaborate with diagnostics firms for targeted therapies. - Conduct post-market studies to demonstrate safety and efficacy, reinforcing the drug’s positioning.

---

10. Key Takeaways

• Market Outlook: Dronedarone's market share is constrained by its niche positioning, with forecasts indicating significant revenue decline post-patent expiry (anticipated around 2024-2025).
• Growth Opportunities: Lifecycle extension through new formulations, expanded indications, and targeted patient therapies remains essential for maximizing long-term value.
• Competitive Dynamics: Generics will challenge pricing and margins; strategic differentiation via safety profile or delivery innovations is critical.
• Regulatory Environment: Patents and data exclusivities provide temporary protection; policy shifts can rapidly impact revenues.
• Investment Strategy: Stakeholders should weigh short-term revenues against long-term risks, emphasizing innovation and market expansion efforts.

---

FAQs

Q1: When does the patent protection for dronedarone hydrochloride expire?
A: Patent protections for the original compound likely expired in 2016; however, secondary patents or formulations could extend protection until around 2024, after which generic competition is expected to enter.

Q2: What are the primary competitors to dronedarone in the atrial fibrillation market?
A: Amiodarone remains the dominant global antiarrhythmic, despite safety concerns, with alternative drugs including sotalol and other class III agents representing minor market shares.

Q3: How does the safety profile of dronedarone influence its market adoption?
A: Dronedarone's reduced toxicity compared to amiodarone makes it suitable for patients intolerant to other therapies, thereby positioning it as a safer alternative in specific cases. However, clinical efficacy remains a key determinant of market uptake.

Q4: What strategies can extend the commercial life of dronedarone?
A: Formulation innovations, new therapeutic indications, combination therapies, and targeted patient recruitment can help prolong market relevance.

Q5: How do regulatory policies impact the future revenues of dronedarone?
A: Patent protections and data exclusivities temporarily restrict generic entry, but policy shifts favoring generic drugs and cost containment can accelerate revenue decline once protections lapse.

---

References

[1] Chugh, S. S., et al. (2020). Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2017 study. Circulation, 141(5), 447-460.

[2] Lavie, C. J., et al. (2022). Atrial fibrillation prevalence and management: global perspectives. Nature Reviews Cardiology, 19, 569–585.

---

This comprehensive analysis aims to equip investors, industry strategists, and stakeholders with robust insights for informed decision-making regarding dronedarone hydrochloride.